MEDI5083 + tremelimumab

MEDI5083 + tremelimumab is an investigational combination therapy developed for advanced solid tumors. MEDI5083 is a CD40 agonist fusion protein that targets the CD40 receptor on the surface of antigen presenting cells, aiming to stimulate immune activation against tumors. Tremelimumab is a fully human monoclonal antibody that blocks CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), a negative regulator of T-cell activation, thus enhancing anti-tumor immune responses. Preclinical models and clinical study rationale suggest that simultaneous activation of CD40 (via MEDI5083) and blockade of CTLA-4 (via tremelimumab) could augment immune-mediated tumor cell killing by overcoming resistance mechanisms and promoting both adaptive and innate immunity. The combination was evaluated in phase 1 clinical trials for various advanced/metastatic solid tumors but study progression was terminated primarily due to toxicity concerns associated with MEDI5083, particularly severe injection-site reactions. MEDI5083 was developed by AstraZeneca/MedImmune[2][3].